# EDGAR Filing Document

**Accession Number:** 0000907654
**File Stem:** 0001104659-25-091774
**Filing Date:** 2025-9
**Character Count:** 23638
**Document Hash:** 44d784b1c8f9b93fc377fc8c8667b80c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-091774.hdr.sgml**: 20250919

**ACCESSION NUMBER**: 0001104659-25-091774

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250919

**DATE AS OF CHANGE**: 20250919

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Oruka Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0000907654
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 363855489
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-51477
- **FILM NUMBER:** 251328125

**BUSINESS ADDRESS:**
- **STREET 1:** 855 OAK GROVE AVE.
- **STREET 2:** SUITE 100
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025
- **BUSINESS PHONE:** 650-606-7910

**MAIL ADDRESS:**
- **STREET 1:** 855 OAK GROVE AVE.
- **STREET 2:** SUITE 100
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ARCA biopharma, Inc.
- **DATE OF NAME CHANGE:** 20090128

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NUVELO INC
- **DATE OF NAME CHANGE:** 20030203

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HYSEQ INC
- **DATE OF NAME CHANGE:** 19970610
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Fairmount Funds Management LLC
- **CENTRAL INDEX KEY:** 0001802528

**ORGANIZATION NAME:**
- **EIN:** 364841215
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 200 BARR HARBOR DRIVE
- **STREET 2:** SUITE 400
- **CITY:** WEST CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428
- **BUSINESS PHONE:** 267-262-5300

**MAIL ADDRESS:**
- **STREET 1:** 200 BARR HARBOR DRIVE
- **STREET 2:** SUITE 400
- **CITY:** WEST CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 4)**

**ORUKA THERAPEUTICS, INC.**

*(Name of Issuer)*

**Common Stock, $0.001 par value**

*(Title of Class of Securities)*

**687604108**

*(CUSIP Number)*

**Ms. Erin O'Connor**<br>Fairmount Funds Management LLC<br>200 Barr Harbor Drive, Suite 400<br>West Conshohocken PA 19428<br>(267) 262-5300

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**09/17/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **687604108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Fairmount Funds Management LLC** | Name of reporting person<br>**Fairmount Funds Management LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**11162741.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**11162741.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**11162741.00** | Aggregate amount beneficially owned by each reporting person<br>**11162741.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**19.99%** | Percent of class represented by amount in Row (11)<br>**19.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IA** | Type of Reporting Person (See Instructions)<br>**IA** | |

---

**Comment for Reporting Person:** The securities (a) include (i) 1,131,954 shares of common stock, $0.001 par value per share (the "Common Stock"), 1,253,572 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants and 6,203,907 shares of Common Stock issuable upon conversion of 74,447 shares of Series B non-voting convertible preferred stock, par value $0.001 per share (the "Series B Preferred Stock"), directly held by Fairmount Healthcare Fund II L.P., a Delaware limited partnership ("Fund II"), and (ii) 2,573,308 shares of Common Stock directly held by Fairmount Healthcare Co-Invest III L.P., a Delaware limited partnership ("Co-Invest"), and (b) exclude (i) 4,044,092 shares of Common Stock issuable upon exercise of Pre-Funded Warrants and (ii) 5,224,242 shares of Common Stock issuable upon conversion of 62,691 shares of Series B Preferred Stock, in each case directly held by Fund II. The exercise of the Pre-Funded Warrants is subject to a beneficial ownership limitation of 9.99% of the outstanding Common Stock and the conversion of the Series B Preferred Stock is subject to a beneficial ownership limitation of 19.99%. The securities exclude shares of Common Stock issuable upon exercise of Pre-Funded Warrants and conversion of shares of Series B Preferred Stock in excess of such beneficial ownership limitations. At such time as Fairmount Funds Management LLC, a Delaware limited liability company and Securities and Exchange Commission registered investment adviser under the Investment Advisers Act of 1940 ("Fairmount"), and its affiliates beneficially own 9.0% or less of the Common Stock, the beneficial ownership limitation with respect to the Series B Preferred Stock will automatically reduce to 9.99%.

Row 13 is based on 55,841,629 shares of Common Stock outstanding as of September 17, 2025, consisting of (i) 37,450,745 shares of Common Stock outstanding as of July 31, 2025, as reported in the Company's most recent Quarterly Report on Form 10-Q, (ii) a total of 10,933,405 shares of Common Stock issued in the Company's private placement on September 17, 2025, as reported by the Company, (iii) the 1,253,572 shares of Common Stock underlying the Pre-Funded Warrants, and (iv) the 6,203,907 shares of Common Stock underlying the 74,447 shares of Series B Preferred Stock owned by the Reporting Persons, subject to the respective beneficial ownership limitations.

| **CUSIP No.** | **687604108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Fairmount Healthcare Fund II L.P.** | Name of reporting person<br>**Fairmount Healthcare Fund II L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**8589433.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**8589433.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**8589433.00** | Aggregate amount beneficially owned by each reporting person<br>**8589433.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**15.38%** | Percent of class represented by amount in Row (11)<br>**15.38%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** The securities (a) include 1,131,954 shares of Common Stock, 1,253,572 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants, and 6,203,907 shares of Common Stock issuable upon conversion of 74,447 shares of Series B Preferred Stock and (b) exclude 4,044,092 shares of Common Stock issuable upon exercise of Pre-Funded Warrants and 5,224,242 shares of Common Stock issuable upon conversion of 62,691 shares of Series B Preferred Stock. The exercise of the Pre-Funded Warrants is subject to a beneficial ownership limitation of 9.99% of the outstanding Common Stock and the conversion of the Series B Preferred Stock is subject to a beneficial ownership limitation of 19.99%. The securities exclude shares of Common Stock issuable upon exercise of Pre-Funded Warrants and conversion of shares of Series B Preferred Stock in excess of such beneficial ownership limitations. At such time as Fairmount and its affiliates beneficially own 9.0% or less of the Common Stock, the beneficial ownership limitation with respect to the Series B Preferred Stock will automatically reduce to 9.99%.

Row 13 is based on 55,841,629 shares of Common Stock outstanding as of September 17, 2025, consisting of (i) 37,450,745 shares of Common Stock outstanding as of July 31, 2025, as reported in the Company's most recent Quarterly Report on Form 10-Q, (ii) a total of 10,933,405 shares of Common Stock issued in the Company's private placement on September 17, 2025, as reported by the Company, (iii) the 1,253,572 shares of Common Stock underlying the Pre-Funded Warrants, and (iv) the 6,203,907 shares of Common Stock underlying the 74,447 shares of Series B Preferred Stock owned by Fund II, subject to the respective beneficial ownership limitations.

| **CUSIP No.** | **687604108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Fairmount Healthcare Co-Invest III L.P.** | Name of reporting person<br>**Fairmount Healthcare Co-Invest III L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2573308.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2573308.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2573308.00** | Aggregate amount beneficially owned by each reporting person<br>**2573308.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.32%** | Percent of class represented by amount in Row (11)<br>**5.32%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** The securities include 2,573,308 shares of Common Stock.

Row 13 is based on 48,384,150 shares of Common Stock outstanding as of September 17, 2025, consisting of (i) 37,450,745 shares of Common Stock outstanding as of July 31, 2025, as reported in the Company's most recent Quarterly Report on Form 10-Q, and (ii) a total of 10,933,405 shares of Common Stock issued in the Company's private placement on September 17, 2025, as reported by the Company.

| **CUSIP No.** | **687604108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Peter Evan Harwin** | Name of reporting person<br>**Peter Evan Harwin** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**11162741.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**11162741.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**11162741.00** | Aggregate amount beneficially owned by each reporting person<br>**11162741.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**19.99%** | Percent of class represented by amount in Row (11)<br>**19.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** The information in the "Comments" to the cover page for Fairmount Funds Management LLC above is hereby incorporated by reference.

| **CUSIP No.** | **687604108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Tomas Kiselak** | Name of reporting person<br>**Tomas Kiselak** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**2B** | Citizenship or place of organization<br>**2B** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**11162741.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**11162741.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**11162741.00** | Aggregate amount beneficially owned by each reporting person<br>**11162741.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**19.99%** | Percent of class represented by amount in Row (11)<br>**19.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** The information in the "Comments" to the cover page for Fairmount Funds Management LLC above is hereby incorporated by reference.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.001 par value

**(b) Name of Issuer:**
ORUKA THERAPEUTICS, INC.

**(c) Address of Issuer's Principal Executive Offices:**
855 Oak Grove Avenue, Suite 100, Menlo Park, CA, 94025

This Amendment No. 4 amends and supplements the statement on Schedule 13D originally filed withthe Securities and Exchange Commission (the "SEC") on September 6, 2024, Amendment No. 1 on
September 13, 2024, Amendment No. 2 on November 21, 2024, and Amendment No. 3 on March 10, 2025 (as amended, the "Statement" or the "Schedule 13D") by the Reporting Persons with respect to the Common Stock of the Company. Unless otherwise defined herein, capitalized terms used in this Amendment No. 4 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.

**Item 4. Purpose of Transaction**

Item 4 of the Statement is hereby amended and supplemented as follows:

Subscription Agreement

On September 17, 2025, the Company entered into a securities purchase agreement (the "Subscription Agreement") for a private investment in public equity ("PIPE") with certain institutional and accredited investors, including Fund II. The PIPE closed on September 19, 2025. Pursuant to the terms of the Subscription Agreement, Fund II purchased a total of 333,340 shares of Common Stock for investment purposes at a purchase price of $15.00 per share.

The foregoing description of the Subscription Agreement does not purport to be complete and is qualified in its entirety by reference to the form of the Subscription Agreement, which the Reporting Persons anticipate will be filed as an exhibit to the Company's upcoming Current Report on Form 8-K.

Registration Rights Agreement

In connection with the PIPE, the Company and investors participating in the PIPE, including Fund II, entered into a registration rights agreement (the "Registration Rights Agreement"), pursuant to which the Company is required to prepare and file an initial registration statement with the U.S. Securities and Exchange Commission no later than October 15, 2025 registering for resale under the Securities Act of 1933, as amended, the shares of Common Stock purchased by the investors in the PIPE. The Registration Rights Agreement also provides that the Company is required to pay certain expenses relating to such registrations and indemnify the applicable securityholders against certain liabilities.

The foregoing summary of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the form of Registration Rights Agreement, which the Reporting Persons anticipate will be filed as an exhibit to the Company's upcoming Current Report on Form 8-K.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information in rows 11 and 13 of each of the cover pages (including the explanatory note in the "Comments") of this Amendment No. 4 is incorporated by reference herein.

**(b)**
The information in rows 7 through 10 of each of the cover pages of this Amendment No. 4 is incorporated by reference herein.

The Reporting Persons' securities (a) include (i) 1,131,954 shares of Common Stock, 1,253,572 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants and 6,203,907 shares of Common Stock issuable upon conversion of 74,447 shares of Series B Preferred Stock, directly held by Fund II, and (ii) 2,573,308 shares of Common Stock directly held by Co-Invest, and (b) exclude (i) 4,044,092 shares of Common Stock issuable upon exercise of Pre-Funded Warrants and (ii) 5,224,242 shares of Common Stock issuable upon conversion of 62,691 shares of Series B Preferred Stock, in each case directly held by Fund II. The exercise of the Pre-Funded Warrants is subject to a beneficial ownership limitation of 9.99% of the outstanding Common Stock and the conversion of the Series B Preferred Stock is subject to a beneficial ownership limitation of 19.99%. The securities exclude shares of Common Stock issuable upon exercise of Pre-Funded Warrants and conversion of shares of Series B Preferred Stock in excess of such beneficial ownership limitations. At such time as Fairmount and its affiliates beneficially own 9.0% or less of the Common Stock, the beneficial ownership limitation with respect to the Series B Preferred Stock will automatically reduce to 9.99%.

**(c)**
On September 17, 2025, Fund II purchased a total of 333,340 shares of Common Stock in the PIPE at a price of $15.00 per share, for an aggregate of $5,000,100.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Fairmount Funds Management LLC

**Signature:** /s/ Peter Harwin

**Name/Title:** Peter Harwin, Managing Member

**Date:** 09/19/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Fairmount Healthcare Fund II L.P.

**Signature:** /s/ Peter Harwin

**Name/Title:** Peter Harwin, Managing Member

**Date:** 09/19/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Fairmount Healthcare Co-Invest III L.P.

**Signature:** /s/ Peter Harwin

**Name/Title:** Peter Harwin, Managing Member

**Date:** 09/19/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Peter Evan Harwin

**Signature:** /s/ Peter Harwin

**Name/Title:** Peter Harwin

**Date:** 09/19/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Tomas Kiselak

**Signature:** /s/ Tomas Kiselak

**Name/Title:** Tomas Kiselak

**Date:** 09/19/2025